Seelos Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.92
- Today's High:
- $1.06
- Open Price:
- $1.02
- 52W Low:
- $0.58
- 52W High:
- $1.66
- Prev. Close:
- $1.01
- Volume:
- 905773
Company Statistics
- Market Cap.:
- $138.83 million
- Book Value:
- -0.38
- Revenue TTM:
- $1.14 million
- Operating Margin TTM:
- -4855.94%
- Gross Profit TTM:
- $-46649000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -107.57%
- Return on Equity TTM:
- -584.2%
Company Profile
Seelos Therapeutics Inc had its IPO on 1999-04-19 under the ticker symbol SEEL.
The company operates in the Healthcare sector and Biotechnology industry. Seelos Therapeutics Inc has a staff strength of 16 employees.
Stock update
Shares of Seelos Therapeutics Inc opened at $1.02 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.92 - $1.06, and closed at $0.95.
This is a -5.94% slip from the previous day's closing price.
A total volume of 905,773 shares were traded at the close of the day’s session.
In the last one week, shares of Seelos Therapeutics Inc have slipped by -12.84%.
Seelos Therapeutics Inc's Key Ratios
Seelos Therapeutics Inc has a market cap of $138.83 million, indicating a price to book ratio of 15.098 and a price to sales ratio of 421.8987.
In the last 12-months Seelos Therapeutics Inc’s revenue was $1.14 million with a gross profit of $-46649000 and an EBITDA of $-27706000. The EBITDA ratio measures Seelos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Seelos Therapeutics Inc’s operating margin was -4855.94% while its return on assets stood at -107.57% with a return of equity of -584.2%.
In Q2, Seelos Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Seelos Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Seelos Therapeutics Inc’s profitability.
Seelos Therapeutics Inc stock is trading at a EV to sales ratio of 549.6804 and a EV to EBITDA ratio of -1.3376. Its price to sales ratio in the trailing 12-months stood at 421.8987.
Seelos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $11.89 million
- Total Liabilities
- $56.11 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Seelos Therapeutics Inc ended 2024 with $11.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $11.89 million while shareholder equity stood at $-47180000.00.
Seelos Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $56.11 million in other current liabilities, 124000.00 in common stock, $-257671000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.84 million and cash and short-term investments were $5.84 million. The company’s total short-term debt was $12,386,000 while long-term debt stood at $2.96 million.
Seelos Therapeutics Inc’s total current assets stands at $11.85 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $431000.00 compared to accounts payable of $6.44 million and inventory worth $5.42 million.
In 2024, Seelos Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Seelos Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.95
- 52-Week High
- $1.66
- 52-Week Low
- $0.58
- Analyst Target Price
- $3.25
Seelos Therapeutics Inc stock is currently trading at $0.95 per share. It touched a 52-week high of $1.66 and a 52-week low of $1.66. Analysts tracking the stock have a 12-month average target price of $3.25.
Its 50-day moving average was $1.28 and 200-day moving average was $0.96 The short ratio stood at 5.13 indicating a short percent outstanding of 0%.
Around 281.5% of the company’s stock are held by insiders while 2035.9% are held by institutions.
Frequently Asked Questions About Seelos Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson’s disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.